"This study has very positive implications in the fight against vCJD, the fatal human form of Mad Cow Disease, which is perhaps the greatest emerging threat to the blood supply", commented Pierre Laurin, President and CEO of ProMetic. "These results also demonstrate what can be achieved with PRDT's proprietary ligand technology", he added.
